Nationwide prospective survey of secondary myelofibrosis in Japan: superiority of DIPSS-plus to MYSEC-PM as a survival risk model

Blood Cancer J. 2023 Jul 19;13(1):110. doi: 10.1038/s41408-023-00869-9.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Japan / epidemiology
  • Primary Myelofibrosis*
  • Prognosis
  • Prospective Studies
  • Thrombocythemia, Essential*